Who
James C. Momtazee
Director
Company insider
Files Form 4 as: Director, Roivant Sciences; Director and 10% owner, BridgeBio Pharma; Director, PRA Health Sciences; Chief Executive Officer, Montes Archimedes Acquisition; Director, Entellus Medical; Director, Jazz Pharmaceuticals; Director, Alliance Imaging Inc /de/.
In numbers
- Trades disclosed
- 105
- Buys
- 1
- Sells
- 1
- Bought
- $1.2M
- Sold
- $88K
- Companies
- 7
- Companies where not an officer
- 6
- First trade
- 3 Jan 2006
- Last trade
- 16 Sep 2026
- Last filed
- 18 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 16 Sep 2026filed 18 Sep 2026 | ROIV Roivant SciencesBiotechnology | SEC FORM 4 Code A | —5,054 at $0.00 | filing |
| 16 Sep 2026filed 18 Sep 2026 | ROIV Roivant Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,531 at $0.00 | filing |
| 16 Sep 2026filed 18 Sep 2026 | ROIV Roivant Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,531 at $0.00 | filing |
| 16 Sep 2026filed 18 Sep 2026 | ROIV Roivant SciencesBiotechnology | SEC FORM 4 Code A | —5,054 at $0.00 | filing |
| 10 Sep 2026filed 14 Sep 2026 | ROIV Roivant SciencesBiotechnology | SEC FORM 4 Code F | $119K2,905 at $40.94 | filing |
| 10 Sep 2026filed 14 Sep 2026 | ROIV Roivant SciencesBiotechnology | SEC FORM 4 Code F | $119K2,905 at $40.94 | filing |
| 17 Jul 2026filed 21 Jul 2026 | ROIV Roivant SciencesBiotechnology | SEC FORM 4 Code A | —405 at $0.00 | filing |
| 17 Jul 2026filed 21 Jul 2026 | ROIV Roivant SciencesBiotechnology | SEC FORM 4 Code A | —405 at $0.00 | filing |
| 22 Jun 2026filed 24 Jun 2026 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Code A | —3,990 at $0.00 | filing |
| 22 Jun 2026filed 24 Jun 2026 | BBIO BridgeBio Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,277 at $0.00 | filing |
| 22 Jun 2026filed 24 Jun 2026 | BBIO BridgeBio Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,277 at $0.00 | filing |
| 22 Jun 2026filed 24 Jun 2026 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Code A | —3,990 at $0.00 | filing |
| 17 Apr 2026filed 21 Apr 2026 | ROIV Roivant SciencesBiotechnology | SEC FORM 4 Code A | —469 at $0.00 | filing |
| 17 Apr 2026filed 21 Apr 2026 | ROIV Roivant SciencesBiotechnology | SEC FORM 4 Code F | $2,80494 at $29.83 | filing |
| 17 Apr 2026filed 21 Apr 2026 | ROIV Roivant SciencesBiotechnology | SEC FORM 4 Code A | —469 at $0.00 | filing |
| 17 Apr 2026filed 21 Apr 2026 | ROIV Roivant SciencesBiotechnology | SEC FORM 4 Code F | $2,80494 at $29.83 | filing |
| 20 Jan 2026filed 22 Jan 2026 | ROIV Roivant SciencesBiotechnology | SEC FORM 4 Code A | —609 at $0.00 | filing |
| 20 Jan 2026filed 22 Jan 2026 | ROIV Roivant SciencesBiotechnology | SEC FORM 4 Code F | $2,804122 at $22.98 | filing |
| 20 Jan 2026filed 22 Jan 2026 | ROIV Roivant SciencesBiotechnology | SEC FORM 4 Code A | —609 at $0.00 | filing |
| 20 Jan 2026filed 22 Jan 2026 | ROIV Roivant SciencesBiotechnology | SEC FORM 4 Code F | $2,804122 at $22.98 | filing |
News
Jazz Pharmaceuticals gets Cramer's vote of confidenceJAZZ · aol.com · 14 Oct 2026Critical Analysis: vTv Therapeutics (NASDAQ:VTVT) and Jazz Pharmaceuticals (NASDAQ:JAZZ)JAZZ · tickerreport.com · 12 Oct 2026Cramer's lightning round: 'I'm going to say yes to Jazz Pharmaceuticals'JAZZ · cnbc.com · 10 Oct 2026
0 headlines in the last 90 days name James C. Momtazee; 3 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.